Tenofovir disoproxil fumarate (TDF) 300 mg

DRUG2 trials

Sponsors

Janssen R&D Ireland, Myanmar Oxford Clinical Research Unit

Conditions

Acquired Immunodeficiency SyndromeHIV Infections

Phase 2

TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients

CompletedNCT00896051

Janssen R&D IrelandAcquired Immunodeficiency Syndrome, HIV Infections

Start: 2009-08-31End: 2012-04-30Updated: 2013-09-30

Unknown Phase

PrEP Among MSM and TG in Myanmar

CompletedNCT04781426

Myanmar Oxford Clinical Research UnitHIV Infections

Start: 2020-10-28End: 2021-08-31Updated: 2022-03-11

Related Papers

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

AIDS Research and Treatment2015-01-014 citations